drugset / Trial / NCT05952947
HRYZ-T101 Injection for HPV18 Positive Solid Tumor
NaSingle-groupOpen-labelTreatment
Summary
A multicenter, open label, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 injection for HPV18 positive solid tumor. The study will investigate RP2D of HRYZ-T101 TCR-T cell injection.
Timeline
- Start
- 2023-11-01
- Primary completion
- 2027-12
- Completion
- 2028-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HRYZ-T101 | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 250 mg/m2 | — |
| Background | Fludarabine | Small molecule | 25 mg/m2 | — |